CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Definitions and classifications of bifurcation lesions and treatment Definition, classification and diagnosis of pulmonary hypertension Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systematic Review and Individual Patient Data Meta-analysis of Randomized Clinical Trials Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial TRAP1 drives smooth muscle cell senescence and promotes atherosclerosis via HDAC3-primed histone H4 lysine 12 lactylation IVUS-Guided vs Angiography-Guided PCI in Patients With Diabetes With Acute Coronary Syndromes: The IVUS-ACS Trial Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction Viridans Streptococcal Biofilm Evades Immune Detection and Contributes to Inflammation and Rupture of Atherosclerotic Plaques
|<<... 170 171 172 173 174 175 176 177 >>|

Original Research

JOURNAL：CBSMD Article Link

TAVR后的冠状动脉介入

CBSMD

Pre-reading


接受经导管主动脉瓣置换术(TAVR)治疗的患者的冠状动脉事件的累积风险较高，冠状动脉通路是否良好对于后续的冠脉介入是个挑战，最新一期的JACC Intervention为TAVR及后续的冠脉介入特刊

1. “Coronary Access After TAVR” 介绍了真实世界中通过CT明确的TAVR术后冠状动脉通路不良（unfavorable coronary access）患者的冠脉介入成功率数据后发现：

1）TAVR术后冠脉通路不良患者的冠脉介入成功率低于冠状动脉通路良好的患者。Evolut R/Evolut PRO 组(0.0% vs. 77.8%; p = 0.003)，SAPIEN 3 组(33.3% vs. 91.4%; p = 0.003) ；

2）提出了TAVR术中有助于保持良好冠状动脉通路的技术细节。


2. “Coronary Access After TAVR With a Self-Expanding Bioprosthesis: Insights From Computed Tomography”介绍了通过多层计算机断层CT观察到的经导管心脏瓣膜（THV）中位TAVR 30天后与左、右冠脉开口的相对解剖位置。



3. Low Risk TAVR试验 "Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients"指出TAVR治疗会对低风险患者的冠状通路造成影响, 或引发主动脉瓣再干预（TAVR-in-TAVR）时的冠脉阻塞。



4. “Coronary Protection to Prevent Coronary Obstruction During TAVR：A Multicenter International Registry”则比较了TAVR术后冠脉保护的两种方案，3年随访结果显示:

1) 通过支架保护冠脉开口后的心源性死亡率显著低于导丝保护后的心源性死亡率（7.8% vs. 15.8%, adjusted hazard ratio: 0.42; 95% confidence interval: 0.14 to 1.28; p = 0.13）;且通过置入支架保护的TAVR患者的明确的支架内血栓发生率不高（0.9%）；

2）通过导丝保护冠脉开口的患者需要预防延迟性的冠脉闭塞（delayed coronary occlusions），发生率为4.3%。



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top